Challenges and Strategies for a Thorough Characterization of Antibody Acidic Charge Variants

Heterogeneity of therapeutic Monoclonal antibody (mAb) drugs are due to protein variants generated during the manufacturing process. These protein variants can be critical quality attributes (CQAs) depending on their potential impact on drug safety and/or efficacy. To identify CQAs and ensure the dr...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Y. Diana, Cadang, Lance, Bol, Karenna, Pan, Xiao, Tschudi, Katherine, Jazayri, Mansour, Camperi, Julien, Michels, David, Stults, John, Harris, Reed J., Yang, Feng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9687119/
https://www.ncbi.nlm.nih.gov/pubmed/36354552
http://dx.doi.org/10.3390/bioengineering9110641

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9687119/
https://www.ncbi.nlm.nih.gov/pubmed/36354552
http://dx.doi.org/10.3390/bioengineering9110641

Ejemplares similares